April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Lack of TG2 increases fat storage and lowers cell cleanup in skin oil cells.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
64 citations
,
August 1999 in “The American journal of medicine” The transscrotal testosterone patch normalizes hormone levels in men with AIDS and weight loss but does not improve weight, body mass, or quality of life.
24 citations
,
January 2017 in “International Journal of Trichology” February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
February 2025 in “Advanced Composites and Hybrid Materials” Glutamic acid microneedle patches promote better hair growth than traditional treatments.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
August 2025 in “Bioactive Materials” Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.
14 citations
,
August 2019 in “Dermatologic Therapy” September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Transglutaminase 2 may control sebocyte maturation and lipid metabolism.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
4 citations
,
January 2019 in “Einstein (São Paulo)” Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
6 citations
,
October 2021 in “Brain Sciences” Dutasteride may help reduce brain inflammation and improve cognition.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
A new topical treatment using micelles shows promise for safer and more effective hair regrowth in androgenetic alopecia.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
October 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
4 citations
,
March 2023 in “IP International Journal of Comprehensive and Advanced Pharmacology” The new drug delivery system improves exemestane's absorption and effectiveness.
2 citations
,
February 2023 in “F&S Reports” Elagolix did not effectively treat polycystic ovary syndrome.
13 citations
,
December 2020 in “BMJ Open Diabetes Research & Care” Changes in SHBG levels don't predict diabetes risk reduction.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
16 citations
,
March 2020 in “Journal of The American Academy of Dermatology” Oral bicalutamide is safe and effective for female hair loss.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.